Bio-Rad Laboratories (BIO) and Qiagen (QGEN) announced that the companies have agreed to settle their patent dispute pending in the U.S. District Court of Delaware pursuant to a global settlement and patent cross-licensing agreement relating to digital PCR technology. The settlement provides for a cross-licensing agreement between Bio-Rad and Qiagen granting each company mutual rights to their respective digital PCR technologies.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BIO:
- Evelo Bio (NASDAQ:EVLO) Gains on Sublease Termination with Bio-Rad
- Evelo enters into termination and surrender pact with Bio-Rad
- Bio-Rad announces up to $500M share repurchase program
- Wells Fargo Predicts up to 125% Rally for These 2 Stocks — Here’s Why They Have Solid Upside
- Bio-Rad initiated with an Overweight at Wells Fargo